ETX.L Regulatory News (ETX)

22 February 2013

e-Therapeutics plc ("e-Therapeutics" or the "Company")

Director/PDMR Shareholding

e-Therapeutics plc (AIM: ETX), the drug discovery and development company with a proprietary platform in network pharmacology, announces that on 21 February 2013 Deborah Young transferred her interest in 10,310,241 shares (being the whole of her share interest in the Company) to her husband Professor Malcolm Young, CEO.

Before the transfer, Professor Young's total beneficial interest in the Company of 21,022,742 ordinary shares, representing 15.21% of the total issued share capital of the Company, consisted of an indirect interest in 377,784 ordinary shares (held through Professor Young's interest in Novotech Investment Limited and Novotech Syndicate LLP), and a direct beneficial interest of 20,644,958 ordinary shares in the Company, of which 10,334,717 shares were held by Professor Young and 10,310,241 shares were held by Mrs Young. Following the transfer, the overall beneficial interest remains unchanged, but Professor Young's direct beneficial interest of 20,644,958 ordinary shares, representing 14.94% of the total issued share capital, is now fully held by him.

As a consequence of the transfer of share interest, there is no change to the aggregate number of shares the subject of irrevocable undertakings relating to the proposed placings of shares announced on 11 February 2013. The shares which were the subject of Deborah Young's consent to the Rule 9 accelerated whitewash referred to in the 11 February 2013 announcement are now subject to the equivalent consent given by Professor Young at that time.

-Ends-

For more information, please contact:

e-Therapeutics plc

Daniel Elger

Tel: +44 (0) 79 0991 5068

www.etherapeutics.co.uk 

Panmure Gordon (UK) Limited

Corporate Finance: Fred Walsh / Grishma Patel

Corporate Broking: Hannah Woodley

Tel: +44 (0) 20 7886 2500

www.panmure.com